Recent news on Reyataz

Approvals: Herceptin, Reyataz, and Peg-Intron  -  May 21, 2007
Medscape (subscription)On May 2, Health Canada approved a 300 mg capsule formulation of atazanavir sulfate (Reyataz, Bristol-Myers Squibb Canada) for use with other antiretroviral

Health Canada approves Reyataz (atazanavir sulfate) 300 mg single ...  -  May 17, 2007
PharmaLive.com (press release),Taken once daily along with ritonavir and food as part of an anti-HIV drug regimen, the REYATAZ 300 mg single capsule formulation can replace two REYATAZ

Pharmaceutical Companies Should 'Broaden' Efforts To Provide ...  -  May 17, 2007
Kaiser network.org,...and Bristol-Meyers Squibb has granted licenses to drug makers in India and Southern Africa to develop its antiretroviral Reyataz for no royalties,

International panel issues new HIV/HCV co-infection guidelines  -  May 24, 2007
Aidsmap,Although atazanavir (Reyataz) and indinavir (Crixivan) can cause elevated bilirubin levels, this does not reflect liver damage.

Doctors, life-saving drugs and the poor  -  May 17, 2007
Bangkok Post,Bristol-Meyers Squibb licensed its second-line drug, Reyataz, completely free of royalties to generic manufacturers for India and southern Africa.

Bristol-Myers Squibb Company Reports First Quarter 2007 Financial ...  -  Apr 26, 2007
PharmaLive.com (press release),Ltd. -- Sales of REYATAZ®, a protease inhibitor for the treatment of human immunodeficiency virus (HIV), increased 27%, including a 3% favorable foreign

Bristol-Myers Profit Slips On Generic Competition  -  Apr 26, 2007
Forbes,Sustiva sales of $226 million exceeded his estimate of $214 million; and Reyataz sales of $263 million passed his forecast of $260 million.

Bristol-Myers 1st-quarter profit drops on lower drug sales, CEO's ...  -  Apr 26, 2007
San Diego Union Tribune,Sales of newer products picked up, with AIDS drug Reyataz jumping 27 percent to $263 million and Abilify, an anti-psychotic, rising 29 percent to $366

Bristol-Myers 1Q Profit Falls  -  Apr 26, 2007
Forbes,Sales of newer products picked up, with AIDS drug Reyataz jumping 27 percent to $263 million from $207 million. Sales of Abilify, an anti-psychotic,

Bristol-Myers 1st-quarter profit drops on lower drug sales, CEO's ...  -  Apr 26, 2007
San Diego Union Tribune,Bristol-Myers did see sales of newer products pick up, with AIDS drug Reyataz jumping 27 percent to $263 million from $207 million.

Bristol Names Cornelius Chief, Beats Profit Estimates (Update2)  -  Apr 26, 2007
BloombergSales of the HIV treatment Reyataz grew 27 percent to $263 million. Avapro for hypertension increased 16 percent to $270 million.

Bristol-Myers Squibb relieved to see Plavix back on track  -  Apr 27, 2007
Pharma Times (subscription),The firm's HIV drugs also made a solid contribution, with revenues from its Sustiva (efavirenz) franchise rising 29% to $226 million and Reyataz

Bristol-Myers Squibb Company Reports First Quarter 2007 Financial ...  -  26 Apr 2007
PharmaLive.com (press release),Ltd. -- Sales of REYATAZ®, a protease inhibitor for the treatment of human immunodeficiency virus (HIV), increased 27%, including a 3% favorable foreign

Bristol-Myers 1Q Profit Falls  -  26 Apr 2007
Forbes,Sales of newer products picked up, with AIDS drug Reyataz jumping 27 percent to $263 million from $207 million. Sales of Abilify, an anti-psychotic,

Broadway Actress/HIV Advocate, Sheryl Lee Ralph, Unveils Winning ...  -  Apr 16, 2007
Drug Newswire (press release),I salute the winners of the REYATAZ 'Fight HIV Your Way' Photography Contest for the hope and strength that their art inspires in me and others."

Broadway Actress/HIV Advocate, Sheryl Lee Ralph, Unveils Winning ...  -  Apr 16, 2007
PR Newswire (press release),REYATAZ does not cure HIV or help prevent passing HIV to others. Please see Indication and Important Safety Information about REYATAZ on the next page.

Ralph Reveals Winners of 'Fight HIV Your Way' Contest  -  Apr 16, 2007
Broadway World,Broadway actress Sheryl Lee Ralph (Broadway’s Dreamgirls) today unveiled the winning photographs of Bristol-Myers Squibb Company's Reyataz "Fight HIV Your

Bristol-Myers Squibb announces winners of HIV-related photography ...  -  Apr 18, 2007
The Advocate,Original Broadway Dreamgirls actress Sheryl Lee Ralph announced the winning photographs in Bristol-Myers Squib’s Reyataz “Fight HIV Your Way� photography

AHF launches ad campaign against Bristol-Myers Squibb over ...  -  Feb 28, 2007
News-Medical.net,AHF President Michael Weinstein in a statement said that BMS charges four times as much for Reyataz and Videx in Mexico than it does for the drugs in parts

House Committee Considers Holding Hearings To Investigate Pricing ...  -  Mar 15, 2007
Kaiser network.org,Norvir is used primarily as a booster for other protease inhibitors, such as Bristol-Myers Squibb's Reyataz and Merck's Crixivan.

Two new medicines funded for people with HIV  -  Mar 14, 2007
Scoop.co.nz,...for Kivexa (a combination treatment) Fuzeon (the first fusion inhibitor, a new class of anti-HIV drug) and Reyataz (a new type of protease inhibitor).

International News  -  Mar 2, 2007
New York Blade,...“In Mexico, Bristol-Myers Squibb charges four times as much for Reyataz and Videx as it does in the least-developed countries in Africa and parts of Asia,

'AIDS Drug Prices to Die For' - AIDS Healthcare Foundation Targets ...  -  Feb 23, 2007
PR Newswire (press release),Ad Campaign by US' Largest AIDS Group Criticizes Drug Giant BMS for Charging Four Times as Much for Its Lifesaving AIDS Drugs Reyataz and Videx in Mexico

CSL Biotherapies One of Several New Business Wins for The Hal ...  -  Feb 1, 2007
PharmaLive.com (press release),...industry's highest awards and have successfully launched and promoted numerous premium health care brands, including Prinivil, Coumadin, and Reyataz.

Inside Abbott's tactics to protect AIDS drug  -  Jan 4, 2007
Pittsburgh Post Gazette,Then, in June 2003, Bristol-Myers Squibb Co. introduced a new protease inhibitor called Reyataz. Bristol-Myers presented a study it funded suggesting that

Abbott considered Norvir withdrawal before price hike option in ...  -  Jan 4, 2007
Aidsmap,In 2003 Abbott was facing a serious challenge to its dominance of the US protease inhibitor market following the approval of Bristol Myers Squibb’s Reyataz

Wall Street Journal Examines Reason Abbott Increased Price of ...  -  Jan 3, 2007
Kaiser network.org,Norvir is used primarily as a booster for other protease inhibitors, such as Bristol-Myers Squibb's Reyataz and Merck's Crixivan ( Kaiser Daily HIV/AIDS

Analysis: Settlement positive for BMS  -  Dec 22, 2006
Science Daily (press release)...he anticipates strong performances from Abilify for schizophrenia, the colon cancer treatment Erbitux and Reyataz, a HIV protease inhibitor.

Research and Markets: 2006 Market Research Available On Bristol ...  -  Dec 21, 2006
PharmaLive.com (press release),Reyataz (atazanavir), a potent azapeptide inhibitor of HIV protease, is the first once-daily protease inhibitor to be approved by the FDA.

Four into one for new HIV TREATMENT  -  Dec 20, 2006
Scoop.co.nz (press release),Most recently, PHARMAC has approved funding for a new class of drug (Fuzeon) and for a new type of protease inhibitor (Reyataz).

Settlement positive for BMS  -  Dec 23, 2006
Monsters and Critics.com,...to the resumption of Plavix sales, he anticipates strong performances from Abilify for schizophrenia, the colon cancer treatment Erbitux and Reyataz, a HIV ...

Atazanavir: genetic predictors for hyperbilirubinemia found  -  Dec 17, 2006
Aidsmap,Genetic factors that put people taking the protease inhibitor atazanavir (Reyataz)at risk of severe hyperbilirubinaemia have been identified by Spanish ...

Research and Markets: 2006 Market Research Available On Bristol ...  -  Dec 21, 2006
Business Wire (press release),Reyataz (atazanavir), a potent azapeptide inhibitor of HIV protease, is the first once-daily protease inhibitor to be approved by the FDA. ...

Four into one for new HIV TREATMENT  -  Dec 20, 2006
Scoop.co.nz (press release),Most recently, PHARMAC has approved funding for a new class of drug (Fuzeon) and for a new type of protease inhibitor (Reyataz).

Panacos to Present Data at 46th Annual ICAAC  Sep 20, 2006
...of a clinical trial studying the interaction of bevirimat (PA-457), the Company's lead HIV drug candidate, and the HIV protease inhibitor atazanavir (REYATAZ). ... -Genetic Engineering News

Peter Dolan Ousted  Sep 12, 2006
...company. Bristol's drug pipeline started to mature, and medicines like schizophrenia treatment Abilify and AIDS drug Reyataz were hits. ... -Forbes

“Revolutionaryâ€? HIV drug approved in NZ  Aug 27, 2006
...“This hopefully bodes well for two other medications awaiting funding, Reyataz and Tenofovir, which have been available in Australia for two and four years ... -Gay NZ

Draft BHIVA treatment guidelines: respond by Monday September 4 th  Aug 30, 2006
Alternative boosted PI regimens recommended by BHIVA include boosted fosamprenavir, boosted saquinavir (Invirase and boosted atazanavir (Reyataz. ... -Aidsmap

Bristol-Myers Hurt By Plavix, Saved By Demographics (BMY)  -  Nov 17, 2006
Investopedia,Bristol-Myers Squibb’s three fastest-growing drugs -- Erbitux for cancer, Reyataz for HIV and Ablify for schizophrenia -- combined to make up approximately

UPDATE:Bristol-Myers 3Q Net Down 65% On Generic Competition  -  Nov 16, 2006
Easy Bourse (Communiqués de presse),Reyataz, an HIV treatment, generated sales of $233 million, up 32%. Sales of the Abilify antipsychotic rose 20% to $313 million. Sales of Erbitux, a cancer

UPDATE: Bristol-Myers Reports Lower Profit Due To Generics  -  Nov 16, 2006
Easy Bourse (Communiqués de presse),Sales of the HIV therapy Reyataz jumped 32% to $233 million, while sales of the psychiatric medication Abilify grew 20% to $313 million.

Bristol-Myers Squibb Company Announces Promotion of Andrew ...  -  Nov 15, 2006
PharmaLive.com (press release),As senior vice president of clinical development, he secured the approvals of ABILIFY(R), ERBITUX(R) and REYATAZ(R). Dr. Sigal has more than 20 years of

Bristol-Myers Squibb Company Announces Promotion of Andrew ...  -  Nov 14, 2006
Yahoo! News (press release)As senior vice president of clinical development, he secured the approvals of ABILIFY®, ERBITUX® and REYATAZ®. Dr. Sigal has more than 20 years of combined

Gilead Sciences, Inc. Q2 2006 Earnings Conference Call Transcript ...  Jul 20, 2006
...attained in the first quarter of this year as the number one prescribed NRTI backbone with the top three leading third agents Sustiva, Kaletra, and Reyataz. ... -Seeking Alpha

Acid-reducing agent increases saquinavir levels in HIV-negative ...  Jul 10, 2006
This is a particular concern for the protease inhibitors, notably atazanavir (Reyataz), putting patients at risk of drug resistance and treatment failure. ... -Aidsmap

Better than expected 'real world' benefits seen in highly ...  Jun 22, 2006
...'Real world' experience from a Spanish HIV clinic has found that once-daily boosted atazanavir (Reyataz) in combination with a once-daily nucleoside backbone ... -Aidsmap

Windhover Information's 16th annual Pharmaceutical Strategic ...  Jul 13, 2006
Under his leadership of the development organization, four new medicines came to market: Abilify, Reyataz, Erbitux and Baraclude. ... -Business Wire

US activists 'applaud' darunavir (Prezista, TMC114) pricing  Jun 29, 2006
The company announced last week that the drug will cost less than tipranavir (Aptivus) and is priced virtually the same as atazanavir (Reyataz), representing a ... -Aidsmap

Windhover Information's 2006 Pharmaceutical Strategic Alliances ...  Jun 21, 2006
Sigal has overseen the development of four new medicines currently on the market -- Abilify, Reyataz, Erbitux and Baraclude - and also the full development of ... -PharmaLive.com

Clinical Pharmacology of Antiretroviral Therapy -- New Data for ...  Jun 22, 2006
PIs saquinavir (Invirase, Roche), nelfinavir (Viracept, Agouron Pharmaceuticals), ritonavir (Norvir, Abbott), lopinavir, and atazanavir (Reyataz, Bristol-Myers ... -Medscape (subscription)



Unexpected interaction between heroin substitute and atazanavir ...  Mar 26, 2006
Atazanavir (Reyataz), boosted by low dose ritonavir (Norvir) appears to interact with the opiate substitute, buprenorphine. Doctors ... - Aidsmap

Atazanavir/ritonavir as potent over two years as Kaletra, but has ...  Mar 14, 2006
Atazanavir (Reyataz) with low dose ritonavir is as effective as Kaletra (lopinavir/ritonavir) at suppressing viral load over two years in treatment-experienced ... - Aidsmap

Emcure AIDS drugs to come to the north  Mar 16, 2006
Atazanavir is sold under the brand name Reyataz® (atazanavir sulfate). ... Reyataz® does not cure HIV or prevent passing HIV to others. - Business Standard

Emcure may launch Bristol's AIDS drug by Dec  Mar 11, 2006
Sold by BMS under the brand name Reyataz, Atazanavir is a once-a-day protease inhibitor for AIDS drugs that was approved in the US in mid-2003. ... - Sify

Debate continues over interaction between ritonavir-boosted ...  Mar 22, 2006
...have illustrated that there is still considerable uncertainty about whether it is safe for HIV-positive patients to take atazanavir (Reyataz) alongside stomach ... - Aidsmap

New 48 Week Clinical Trial Data Reported Comparing REYATAZ(R) ...  09 Feb 2006
CROI) provided results on the virologic and immunologic response and the safety profile of the once-daily protease inhibitor REYATAZ® (atazanavir sulfate ... - Yahoo! News

(PRN) - Specialty Metals Industry Group Releases Eleven-Month ...  09 Feb 2006
...[+]. (PRN) - New 48 Week Clinical Trial Data Reported Comparing REYATAZ(R) (Atazanavir Sulfate), With or Without Ritonavir, in Treatment-Naive Patients ... [+. ... - Bolsamania.com

CROI: Treatment Interruptions Prove Dismal News for HIV Patients  Feb 8, 2006
...the patients stopped taking the nucleoside reverse transcriptase backbone of the regimen, but remained on the protease inhibitor Reyataz (atazanavir), boosted ... - MedPage Today

Merck integrase inhibitor strong in highly treatment-experienced ...  Feb 8, 2006
Patients were stratified into two substudies based on concurrent use of atazanavir (Reyataz), which may have a hypotherical effect on MK-0518 plasma ... - Aidsmap

Bristol-Myers Profit Up Despite Sales Dip  Jan 25, 2006
...sales of blood thinner Plavix, the company's best selling product, rose 11 percent to $1.1 billion from $959 million while AIDS drug Reyataz revenue jumped 27 ... - CBS News

Bristol-Myers Squibb hires BM for virology  Jan 10, 2006
Bristol-Myers Squibb has enlisted Burson-Marsteller to replace Ruder Finn on UK virology work, including HIV treatment Reyataz. ... - PRWeek (subscription)

Bristol-Myers Net Rises on Lower Costs; Sales Drop (Update2)  Jan 25, 2006
...last week. Revenue from Bristol-Myers's AIDS treatment Reyataz, introduced in July 2003, rose 27 percent to $188 million. Sales ... - Bloomberg

Bristol-Myers Catches a Cold  Jan 25, 2006
Simply put, double-digit growth from a stable of drugs including Plavix, Abilify, Reyataz, and Erbitux weren't enough to outweigh losses to competition and ... - Motley Fool

Bristol earnings up, but issues warning  Jan 25, 2006
That means strong sales of its leading products -- cancer drug Erbitux, up 38 percent, AIDS treatment Reyataz, up 27 percent, blood-thinner Palvix, up 11 ... - Newark Star Ledger

B-MS sales dip in Q4 on Pravachol competition  Jan 26, 2006
Other products offsetting the impact of generic competition were colorectal cancer drug Erbitux (cetuximab), Reyataz (atazanavir) for HIV, and the ... - Pharma Times (subscription)

Bristol-Myers net triples as sales ease 1%  Jan 25, 2006
...return to sustained growth in 2007. Sales of Reyataz, a treatment for HIV, shot up 27% to $188 million. Its drug Abilify, an anti ... - Investor's Business Daily (subscription)

Roche to share know-how in making protease inhibitors with poorest ...  Jan 13, 2006
...lopinavir/ritonavir), which is offered to least developed and sub-Saharan countries at $500 a year by Abbott Laboratories, Reyataz (atazanavir) boosted with ... - Aidsmap

T-20 helps to prevent mother-to-child transmission of HIV in women ...  Jan 19, 2006
...and the woman was provided with an anti-HIV treatment regimen consisting of abacavir (Ziagen), delavirdine, fosamprenavir (Telzir) and atazanavir (Reyataz). ... - Aidsmap

Healthpoint Names The Hal Lewis Group as Branding and Marketing ...  Jan 11, 2006
...of the industry's highest awards and have successfully launched and promoted numerous premium health care brands, including Prinivil, Coumadin, and Reyataz. ... - PharmaLive.com

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional